Clinical trial
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan…
NCT00074165 · OHSU Knight Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00074165 |
|---|---|
| Title | Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen |
| Official title | A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia |
| Intervention type | Drug |
| Interventions | Rituxan, Cyclophosphamide, Etoposide, Etoposide phosphate, Carboplatin, Sodium thiosulfate, Neupogen, Neulasta, Cytarabine |
| Enrollment | 17 |
| Start date | Jan 1, 2003 |
| Primary completion | Jun 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Dec 11, 2003 |
| Last update posted | Jul 6, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: